focus -WSS

focus

author：hotspot 2025-09-28 10:44:38 Page View：66242

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer cells are shown to suck energy source from immune cells
Next article： Walensky prepares to leave CDC — and Congress — behind

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

AdobeSometimes,anappleadayreallyisjustwhatthedoctorordered.Andforthepastseveralyears,organizationsli

How AI can help patients find reliable information about doctors

AdobeAlmostassoonasChatGPTwasreleasedtothepublic,doctorsbeganfocusingonhowtheycouldharnessartificial

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

KatiePalmer,STAT(left)moderatingtheDoctorvs.ChatGPTsessionduringthe2023STATSummit.STATGenerativeAIto